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The accuracy of mitochondrial protein synthesis is dependent on the coordinated action of
nuclear-encoded mitochondrial aminoacyl-tRNA synthetases (mtARSs) and the mitochon-
drial DNA-encoded tRNAs.The recent advances in whole-exome sequencing have revealed
the importance of themtARS proteins for mitochondrial pathophysiology since nearly every
nuclear gene for mtARS (out of 19) is now recognized as a disease gene for mitochondrial
disease. Typically, defects in each mtARS have been identified in one tissue-specific
disease, most commonly affecting the brain, or in one syndrome. However, mutations in
the AARS2 gene for mitochondrial alanyl-tRNA synthetase (mtAlaRS) have been reported
both in patients with infantile-onset cardiomyopathy and in patients with childhood to
adulthood-onset leukoencephalopathy. We present here an investigation of the effects of
the described mutations on the structure of the synthetase, in an effort to understand the
tissue-specific outcomes of the different mutations. The mtAlaRS differs from the other
mtARSs because in addition to the aminoacylation domain, it has a conserved editing
domain for deacylating tRNAs that have been mischarged with incorrect amino acids. We
show that the cardiomyopathy phenotype results from a single allele, causing an amino acid
change R592W in the editing domain ofAARS2, whereas the leukodystrophymutations are
located in other domains of the synthetase. Nevertheless, our structural analysis predicts
that allmutations reduce the aminoacylation activity of the synthetase, because allmtAlaRS
domains contribute to tRNA binding for aminoacylation. According to our model, the
cardiomyopathy mutations severely compromise aminoacylation whereas partial activity
is retained by the mutation combinations found in the leukodystrophy patients. These
predictions provide a hypothesis for the molecular basis of the distinct tissue-specific
phenotypic outcomes.
Keywords: mitochondrial disease, aminoacyl-tRNA synthetases, alanyl-tRNA synthetase, tissue-specificity, struc-
tural modeling
INTRODUCTION
Mitochondrial protein synthesis produces key subunits of the
oxidative phosphorylation (OXPHOS) complexes that generate
the majority of the ATP for our cells. The protein synthe-
sis in mitochondria requires careful synchrony between two
genomes and cellular compartments, because the protein com-
ponents of its machinery are encoded by the nuclear genome
and imported into mitochondria, whereas the RNA components
(2 rRNAs and 22 tRNAs) are encoded by mitochondrial DNA
(Hallberg and Larsson, 2014). Among the necessary proteins are
the aminoacyl-tRNA synthetases (ARSs) that recognize specific
tRNAs and charge them with cognate amino acids, thus con-
tributing to the initiation and accuracy of the protein synthesis.
Nineteen ARSs function in mammalian mitochondria (mtARSs),
one for each amino acid, except glutamine, which is charged by an
alternative pathway (Nagao et al., 2009).
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Defects of mitochondrial translation are a major cause of
diseases that lead to mitochondrial OXPHOS dysfunction (Rotig,
2011). Since 2007, the mtARS genes have been recognized as
a new group of disease genes affecting mitochondrial protein
synthesis (Konovalova and Tyynismaa, 2013; Diodato et al., 2014a;
Schwenzer et al., 2014). Proteins need to be synthesized in mito-
chondria in all cell types, with the exception of red blood cells,
and thus the tissue-specificity of the phenotypes caused by muta-
tions in the different mtARS genes has been unexpected. Now that
pathogenic mutations have been reported in 15 genes encoding
mtARSs (and in the two genes GARS and KARS encoding dual
localized synthetases for cytoplasmic and mitochondrial transla-
tion), we can, however, conclude that the majority of the mtARS
defects affect the central nervous system. Nevertheless, the range
of CNS phenotypes is also remarkably wide, affecting specific neu-
rons in many cases, and including patients with infantile-, early-
and late-onset of disease.
Central nervous system involvement as the main or sole clin-
ical presentation is found in defects of the mtARSs for aspartate
(DARS2; Scheper et al., 2007), glutamate (EARS2; Steenweg et al.,
2012), methionine (MARS2; Bayat et al., 2012), phenylalanine
(FARS2; Elo et al., 2012), arginine (RARS2; Edvardson et al., 2007),
valine (VARS2; Diodato et al., 2014b), threonine (TARS2; Diodato
et al., 2014b), proline (PARS2; Sofou et al., 2015), asparagine
(NARS2; Sofou et al., 2015), and cysteine (CARS2; Hallmann et al.,
2014). Exceptions are the mutations in the genes for histidyl-tRNA
(HARS2) and leucyl-tRNA (LARS2) synthetases that cause sen-
sorineural hearing loss and ovarian dysgenesis (Pierce et al., 2011,
2013), for tyrosyl-tRNA synthetase (YARS2) in a combination of
myopathy and anemia (Riley et al., 2010), and for seryl-tRNA
synthetase (SARS2; Belostotsky et al., 2011) in HUPRA, for hype-
ruricemia, pulmonary hypertension, renal failure in infancy, and
alkalosis, syndrome. A common feature for all the defects men-
tioned above is that so far each of them has been described in one
tissue-specific phenotype or in one syndrome.
We identified mutations in the gene for mitochondrial alanyl-
tRNA synthetase (AARS2) in a phenotype that differs from the
other reported mtARS defects, being clinically a fatal early onset
cardiomyopathy (Gotz et al., 2011). Our patients died within the
first 10 months of life with severe cardiomyopathy, having a signif-
icant reduction in OXPHOS complexes in the heart and partially
also in the skeletal muscle and brain. Two other studies have
later reported patients with fatal infantile-onset AARS2 mutations
(Calvo et al., 2012; Taylor et al., 2014). Although cardiomyopa-
thy is not a usual feature of the other mtARS defects, it is typical
in early infancy in many other mitochondrial protein synthesis
defects, such as in those caused by mutations in genes encoding
for mitoribosome subunits MRPL44 and MRPL3 (Galmiche et al.,
2011; Carroll et al., 2013), in tRNA-modifiers MTO1 (Ghezzi et al.,
2012) andGTPBP3 (Kopajtich et al., 2014), and in RNA processing
enzyme ELAC2 (Haack et al., 2013). Remarkably, a recent study
reported AARS2 mutations in patients who developed leukoen-
cephalopathy and ovarian failure, with onset from childhood to
adulthood, and no signs of a cardiomyopathy (Dallabona et al.,
2014). AARS2 has thus been an example of mutations in the same
mtARS gene leading to two very different diseases with dissimilar
tissue involvement.
Themitochondrial alanyl-tRNA(mtAlaRS) synthetase encoded
by AARS2 differs itself from the other mtARSs, because it has
in addition to the aminoacylation domain a conserved editing
domain for deacylatingmischarged tRNAs (Beebe et al., 2003; Guo
et al., 2009b; Gotz et al., 2011). The mischarging results from the
inability of the enzyme’s aminoacylation domain to discriminate
alanine from two other small amino acids, serine and glycine.
In addition, the synthetase has a C-terminal domain, which is
required for cooperative binding of both the aminoacylation and
editing domains to the tRNA (Guo et al., 2009a). We have pre-
viously hypothesized that in our cardiomyopathy patients, the
AARS2 mutation resulting in R592W change, which is located in
the editing domain of the synthetase, might interfere with tRNA
binding, thus preventing editing, and resulting in mistranslation
(Gotz et al., 2011). Based on homology modeling, we now present
structural predictions of all AARS2 missense mutations in the two
different phenotypes, and show that the tissue-specific defects
affect distinct domains of the synthetase but compromise the
aminoacylation with different outcomes. Furthermore, we show
that the AARS2 cardiomyopathy mutation (R592W) is a common
founder mutation and carried by all the identified patients with
the severe infantile-onset phenotype.
MATERIALS AND METHODS
HAPLOTYPE ANALYSIS
Nine single-nucleotide polymorphisms (SNPs) flanking AARS2
gene were selected for haplotype analysis, based on the haplotype
blocks presented previously (Taylor et al., 2014). Genomic DNA
was amplified by PCR using flanking oligonucleotides (sequences
available on request) and Sanger sequenced.
STRUCTURE PREDICTION
For human mtAlaRS homology modeling we used the recently
solved structure of full-length alanyl-tRNA synthetase (AlaRS)
from Archaeoglobus fulgidus as a template. This bacterial AlaRS
is a homodimer with one subunit crystallized with bound tRNA
substrate and an alanyl-adenylate analog in so-called“closed”con-
formation, while the second subunit is in “open,” substrate free
conformation (Naganuma et al., 2014; PDB id 3WQY). “Closed”
conformation of human mtAlaRS was modeled using A chain
in solved A. fulgidus AlaRS structure (3WQY_A), and the “open”
substrate free form was modeled using B chain of the same struc-
ture (3WQY_B). Sequence alignment of human mtAlaRS (985 aa)
and template A. fulgidus AlaRS (906 aa) was done using similar-
ity matrix BLOSUM62. Multiple sequence alignments of human
mtAlaRS and template sequence with a number of prokaryote
and eukaryote homologs were done using PROMALS3D server.
Obtained alignment was then submitted for homology model-
ing to the SWISS-MODEL server. Modeling was performed using
alignment mode using either 3WQY_A or 3WQY_B structure
as template. Resulting “open” and “closed” structures were ana-
lyzed using Discovery Studio v4.1 (Accelrys) software. Overall
architecture and arrangement of secondary structure elements in
the obtained models was similar to those in the template struc-
tures except for two loops, encompassing residues 211–231 and
540–561, which were omitted in the analysis. Docking of the bac-
terial tRNAAla and alanyl-adenylate into the model was done after
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superimposition of template chain A with the modeled human
mtAlaRS using Discovery Studio v4.1 (Accelrys) software.
RESULTS
THE AARS2 c.1774C> T (R592W) IS A FOUNDER MUTATION AND
CARRIED BY EVERY PATIENT WITH THE CARDIOMYOPATHY
PHENOTYPE
Seven patients with infantile-onset cardiomyopathy and AARS2
mutations have been reported (Gotz et al., 2011; Taylor et al., 2014)
and one who died in utero was described to have myopathy, hypo-
tonia and multiple fractures (Calvo et al., 2012). In addition, we
report here three additional patients of Swedish or German origin.
The Swedish patient was a boy born as the second child
of healthy, non-consanguineous parents. An older sibling was
healthy. The pregnancy and delivery were normal. Birth weight
was 3990 g. The Apgar Scores were 2, 5, and 7 at 1, 5, and 10 min.
At birth the boy was floppy, had decreased movements and pre-
sented breathing difficulties needing ventilatory treatment from
the age of 1 h. He was diagnosed with a hypertrophic cardiomy-
opathy involving both the left and right ventricles, and with lactic
acidosis. He was referred for further investigation at the age of
13 days. A skeletal muscle biopsy performed at the age of 14 days
showed a mitochondrial myopathy with ragged red fibers, which
were cytochrome-c oxidase negative, and with increased lipid
droplets. Investigation of isolated skeletal muscle mitochondria
showed decreased activities of complexes I-IV. The cardiomyopa-
thy was progressive and the boy died at the age of 7 weeks of
cardio-respiratory failure. An autopsy was performed and showed
a severely hypertrophic heart that weighed 60 g.
The German patients were twin girls of healthy, non-
consanguineous parents. The pregnancy and delivery were nor-
mal. Birth weights of the first and second twin were 1890 g and
2150 g, respectively. The Apgar Scores were 9, 10, 10, and 6, 8,
9, respectively. Onset of disease in the first twin was at birth
with breathing difficulties needing ventilatory treatment from
the age of 8 h. The second twin was stable and did not need
ventilatory support. The first twin was diagnosed with a hyper-
trophic cardiomyopathy involving mostly the left ventricle and
with lactic acidosis at the age of 8 weeks. A skeletal muscle biopsy
performed at the age of 11 weeks showed a mitochondrial myopa-
thy with cytochrome-c oxidase negative fibers and perimysial
fibrosis as well as reduced activity of coenzyme Q. Investigation of
respiratory chain complexes disclosed reduced activities for com-
plexes I–IV. The cardiomyopathy was progressive and the girl died
at the age of 16 weeks of cardio-respiratory failure. The symptoms
in the second twin started a few weeks later and showed the same
clinical course, she died at the age of 20 weeks.
Out of these eleven patients six were homozygous for the
c.1774C > T (R592W) mutation and five had compound het-
erozygous AARS2 mutations with each of them carrying the same
c.1774C> T (R592W) mutation in one allele (Table 1).
Patients with British or German origin were recently suggested
to share a common disease haplotype for R592W (Taylor et al.,
2014). We present here the haplotypes surrounding this mutation
for patients from Finland, Sweden, and Australia in compari-
son to the British and German patients, which suggest that the
sharedmutation described in eachAARS2 cardiomyopathy patient
originates from a common founder (Figure 1).
Carriers of the c.1774C > T (R592W) mutation can be found
in exome sequencing databases of different populations (Table 2),
with the highestminor allele frequency of 0.0006 in Finland,where
the first AARS2 cardiomyopathy patients were identified.
THE DISTRIBUTION OF THE MUTATED AMINO ACIDS IN
CARDIOMYOPATHY AND LEUKODYSTROPHY SUGGESTS DIFFERENTIAL
MOLECULAR PATHOGENESIS
TheR592Wamino acid change locates to the editing domain of the
mtAlaRS andwe initially hypothesized that it causesmitochondrial
mistranslation,which can be expected to harmOXPHOS assembly
and function by amino acid misincorporation in the subunits
Table 1 | List of all patients reported with mutations inAARS2 that presented with infantile-onset cardiomyopathy.
Mutation (s) Country of origin Age at death Clinical presentation Reference
Homozygous
R592W Finnish 10 months cardiomyopathy, muscle, CNS Gotz et al. (2011)
R592W German 4–5 months (twins) cardiomyopathy, muscle This report
R592W Swedish 7 weeks cardiomyopathy, muscle This report
R592W German 2 months cardiomyopathy, muscle Taylor et al. (2014)
R592W British 11 months cardiomyopathy Taylor et al. (2014)
Compound heterozygous
R592W, L155R Finnish 3 days (sibling died in utero) Cardiomyopathy, muscle, CNS Gotz et al. (2011)
R592W, R329H Australian in utero Stillborn fetus,muscle Calvo et al. (2012)
R592W, A961V British 1.5 months Cardiomyopathy, muscle, CNS Taylor et al. (2014)
R592W, C218Lfs*6 British 3 months Cardiomyopathy Taylor et al. (2014)
R592W,Y539C German 1 month Cardiomyopathy, muscle, CNS Taylor et al. (2014)
All patients were either homozygous or compound heterozygous for c.1774C >T (R592W) mutation. Clinical description regarding muscle and central nervous system
(CNS) involvement is included.
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FIGURE 1 | Patient haplotypes around theAARS2 mutation.The haplotype of the Swedish patient shows recombination 165 kilobases upstream of the
mutation site.
that are synthesized by mitoribosomes (Gotz et al., 2011). The
new AARS2 mutations reported in patients with leukodystrophy
seemed, at first glance, to be scattered along the entire AARS2
gene, with some located in the aminoacylation domain and
some in the editing domain (Dallabona et al., 2014). All of the
leukodystrophy patients had compound heterozygous mutations.
To clarify the range and localization of the mutations in both phe-
notypes, we analyzed them in the actual combinations in which
they were found in the patients (Figure 2). The cardiomyopathy
patients were either homozygous for the editing domain mutation
R592W or had it in combination with a mutation located in the
aminoacylation, editing or the C-terminal domain or with a trun-
cating mutation. Mutations that cause premature termination or
frameshift can be expected to be total loss-of-function alleles with
no stable synthetase present. The mutation spectrum was very
Table 2 | Allele frequency of the mutation leading to amino acid
change R592W in different exome/genome databases. SISU and 1000
Genomes contribute to the larger ExAC database.
Database Total alleles Mutation
alleles
Minor allele
frequency
1000 Genomes
(1000 genomes.org)
5008 1 0.0002
SISU (sisu.fimm.fi) 6646 4 0.0006
EVS (evs.gs.washington.edu) 13006 3 0.0002
ExAC (exac.broadinstitute.org) 126272 35 0.0003
different for the leukodystrophy patients because these presented
combinations of two missense mutations in the aminoacylation
domain or an aminoacylation domain missense mutation with a
truncating mutation, with one exception, which was a combina-
tion of missense mutations in the aminoacylation domain and
the C-terminal domain. Thus none of the missense mutations
in leukodystrophy patients were in the editing domain, which
was in striking contrast to all of the cardiomyopathy patients
(Figure 2).
OVERVIEW OF THE STRUCTURAL MODEL OF HUMAN mtAlaRS
The recent crystal structure of a full-length length AlaRS
(Naganuma et al., 2014) made possible our current com-
plete structural model of the human mtAlaRS, which includes
the arrangement of all three domains: aminoacylation, edit-
ing and C-terminal. The human mtAlaRS and template A.
fulgidus AlaRS sequences shared overall 17.5% identity and
30.9% similarity (Figure 3). Domain-specific sequence iden-
tity and similarity was 17.5 and 31.2% for the aminoacyla-
tion domain, 25.0 and 39.8% for the editing domain and
14.7 and 26.5% for the C-terminal domain, respectively. Each
domain can be further divided into two subdomains: the
aminoacylation domain contains subdomains for aminoacyla-
tion and tRNA recognition, the editing domain consists of
β-barrel and editing core, and the C-terminal or so-called
C-Ala domain consists of helical and globular subdomains
(Figure 4).
Since the template structure of AlaRS of A. fulgidus was resolved
as a dimer,with one subunit in a substrate bound“closed”state and
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FIGURE 2 |AARS2 mutations.The compound heterozygous mutations
found in patients with cardiomyopathy or leukodystrophy are illustrated.
Truncating mutations that are predicted to destabilize the entire synthetase
are marked with dotted lines. The thicker arrows demonstrate recurring
mutations. The AARS2 mutation leading to the R592W amino acid change
has been the only one identified in a homozygous state.
the other in a substrate free“open”state (Naganuma et al., 2014), it
was possible to use bacterial tRNAAla and alanyl-adenylate bound
to the template structure (chain A in 3WQY) for docking into our
model and explore intermolecular interactions within the tertiary
complex (Figure 4). The homologymodeling suggests that human
mtAlaRS shares with A. fulgidus AlaRS the unique structural fea-
tures inherent for all AlaRSs. Firstly, it has a large tRNA-binding
cavity whereas other ARSs adopt cognate tRNAs on their sur-
face. Secondly, all three domains are involved in the binding of
tRNA undergoing aminoacylation. Previous studies have shown
that tRNA binding and the rate of aminoacylation are enhanced
by the C-terminal domain as it has the highest tRNA binding affin-
ity (Guo et al., 2009a). The structure of A. fulgidus AlaRS revealed
that the C-terminal globular subdomain holds the elbow of the
L-shaped tRNAwhile the acceptor stem is fixedwithin the aminoa-
cylation domain by concerted binding to the so-called“safety belt”
(the linker between aminoacylation and editing domains), and
to the tRNA recognition subdomain and the surface of editing
core (Naganuma et al., 2014). We predict the same type of tRNA
binding for aminoacylation also in the modeled human mtAlaRS
(Figure 4). Close inspection of the A. fulgidus AlaRS structure as
well as the modeled tertiary complex of mtAlaRS revealed that
the “safety belt” folds along the surface of the β-barrel in the edit-
ing domain and establishes different interactions with its surface
exposed residues in “open” and “closed” states (Figure 5). This
suggests that the β-barrel may serve as a “buckle” for fastening
the “safety belt” when the tRNA is bound in the aminoacylation
site. In human mtAlaRS the interacting surfaces of the linker and
β-barrel are comprised of different residues than in the template,
but comparison of “open”and“closed”conformations shows rear-
rangements in their interactions upon tRNA binding (Figure 6).
Interestingly, the linker has an amino acid sequence stretch, L494-
Q505,which is highly conservedbetweenmitochondrial homologs
(Figure 6). Modeled structure shows that L502 from this stretch is
involved in hydrophobic interactions predominantly with residues
from β-hairpin (R592–A604) of the β-barrel. Since this motif is
also very conserved between mitochondrial homologs and ori-
ented toward the linker it is likely that these two fragments extend
their interaction by establishing transient contacts upon sliding
of the linker on the surface of the β-barrel during transition
from “open” to “closed” conformations of the enzyme. Therefore,
we propose that the editing domain of mtAlaRS, in addition to
its proofreading activity of deacylating mischarged tRNAs, may
also be involved in the aminoacylation activity of the enzyme by
being involved in the binding of tRNAAla for aminoacylation and
stabilizing position of its acceptor stem within the catalytic site.
STRUCTURAL ANALYSIS OF AARS2 MUTATIONS
We utilized our full-length mtAlaRS homology model to local-
ize all amino acid changes found in mtARS in patients with
cardiomyopathy (L155R, R329H, Y539C, R592W, and A961V)
and leukodystrophy (F50C, A77V, R199C, E405K, and G965R;
Figure 7) to predict their effects on synthetase structure and func-
tion (Table 3). The missense mutations could be divided into
three groups based on the effect on the aminoacylation activity:
loss-of-function, severe, and moderate.
Loss of function
The amino acid changes L155R, R329H, A961V, and G965R
(residues L173, R345, A880, and V884 in A. fulgidus, respectively)
are predicted to impair protein folding and stability resulting in
loss of aminoacylation activity (black color-coded in Figure 7).
Most of these residues are invariant between cytoplasmic, mito-
chondrial, and bacterial homologs of AlaRS and critical for
maintaining the structure. Accordingly, the change L155R was
recently modeled in yeast and had a deleterious effect on cell
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FIGURE 3 | Sequence alignment between human mtAlaRS and
AlaRS from A. fulgidus (3WQY). The alignment was extracted
from multiple sequence alignment of AlaRS homologs from
eukaryotes and prokaryotes using BioEdit software. The
aminoacylation domain is marked with dark gray bar, the editing
domain with cyan, and the C-terminal domain with magenta bars.
Identical/similar amino acid residues in the same position are
marked with colored boxes.
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FIGURE 4 | Overview of the modeled structure of humanAlaRS.
Aminoacylation subdomain (24–312 aa) is in silver, tRNA recognition
subdomain (313–477 aa) of aminoacylation domain is in green, linker (“safety
belt” – 478–529 aa) between tRNA recognition and editing domain is
presented as solvent interpolated charge surface, β-barrel (530–621 aa) and
editing core (622–783 aa) subdomains of editing domain are in pink and cyan,
respectively. C-Ala domain or C-terminal domain is predicted to have helical
(784–874 aa in magenta) and globular (875–985 aa in yellow) subdomains.
R480 and R482 from the linker are predicted to stabilize bound tRNA within
the aminoacylation domain. Backbone of docked tRNA is shown in dark gray.
Docked alanyl-adenylate in the aminoacylation site is shown as stick model
with carbon atoms labeled with magenta. Part of β-barrel subdomain
(592–604 aa) of the editing domain proposed to interact with the linker is
marked with purple (see text).
FIGURE 5 | Analysis of the contact surface between linker (“safety
belt”) and β-barrel of the editing domain in A. fulgidus AlaRS
structure (3WQY), which was used as template for modeling. (A)
Superimposed chains A “closed” form (blue) and B “open” form (pink).
Fragments encompassing residues K474–D589 are shown. For
superimposition T582–V613 fragment was used as tether. (B) Residues
from the linker (“safety belt”) interacting with the surface exposed
residues on the β-barrel in “closed” conformation. Carbon atoms of
interacting amino acid residues are in blue. (C) The position of the same
residues in “open” conformation (carbon atoms in magenta). Hydrophobic
interactions are marked with magenta dashed lines, electrostatic
interactions with orange dashed lines.
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FIGURE 6 | Analysis of the contact surface between linker (“safety belt”)
and β-barrel of the editing domain in modeled human mitochondrial
AlaRS. (A) Superimposed chains A “closed” form (green) and B “open” form
(yellow). Fragments encompassing residues G468-D621 are shown. For
superimposition Q615–L646 fragment was used as tether. (B) Interacting
residues from the linker (”safety belt”) and surface exposed residues on the
β-barrel in ”closed” conformation (shown in khaki). (C) Interacting residue in
the “open” conformation (in orange). Hydrophobic interactions are marked
with magenta dashed lines. Fragment L494–Q505 conserved between
mitochondrial AlaRS homologs is marked with red.
FIGURE 7 | Mapping and function predictions ofAARS2 mutations
associated with cardiomyopathy and leukodystrophy. Domains are
color-coded as in Figure 4. Structural loss-of-function mutations are marked in
black, mutations affecting substrate binding and resulting in severe reduction
in aminoacylation activity are in red, and mutations resulting in moderate
decrease of aminoacylation activity are in orange.
growth suggesting complete absence of aminoacylation activity
(Dallabona et al., 2014). Residues A961 and G965 are impor-
tant for the fold and stability of C-globular subdomain, and
therefore for the architecture of the tRNA binding site. The C-
terminal globular domain is separated from the main body of the
enzyme, so its disruption may not result in overall misfolding.
However, even if the aminoacylation and editing domains remain
stable, disruption of the C-terminal domain’s crucial role in tRNA
binding and orientation is likely to result in severely reduced rates
of aminoacylation.
Severe
The A77V, Y539C, and R592W (residues A99, E525, and D561
in A. fulgidus, respectively) changes are not predicted to affect
Frontiers in Genetics | Genetic Disorders February 2015 | Volume 6 | Article 21 | 8
Euro et al. Structural predictions of AARS2 mutations
Table 3 | Structural analysis of cardiomyopathy and leukodystrophy mutations inAARS2 and assessment of their impact on the synthetase
function based on modeled protein structure.
Amino acid
change
Structural assessment Functional impact on the enzyme Phenotype C
or L
In combination with
Loss-of-function
L155R Architectural residue maintaining structure of
aminoacylation site; mutation impairs
structural stability of the protein during folding
Loss-of-function mutation due to highly
unstable protein
C R592W
R329H Structural residue involved in interaction and
stabilization of two subdomains of the
aminoacylation domain
Loss-of-function mutation due to highly
unstable protein
C R592W
A961V Structural residue, involved in stabilization of
globular subdomain of C-terminal domain,
critical for architecture of tRNA binding surface
Loss-of-function mutation due to unstable
protein and abolished tRNA binding
C R592W
G965R Structural residue, involved in stabilization of
globular subdomain of C-terminal domain,
critical for architecture of tRNA binding surface
Loss-of-function mutation due to unstable
protein and abolished tRNA binding
L E405K
Severe
A77V Catalytic residue; likely affects alanine binding Results in either totally inactive enzyme or
with little aminoacylation activity due to
decreased affinity to alanine
L R199C
Y539C Surface exposed residue within the β-barrel
subdomain of the editing domain, together
with linker secures the position of tRNA within
the aminoacylation site
Dramatic decrease of aminoacylation rate due
to impaired tRNA binding and positioning of
the 3′-end within the active site
C R592W
R592W Surface exposed residue within the β-barrel
subdomain of the editing domain, together
with linker secures the position of tRNA within
the aminoacylation site
Dramatic decrease of aminoacylation rate due
to impaired tRNA binding and positioning of
the 3′-end within the active site
C R592W,Y539C,
R329H, L155R,
A961V, truncating
mutation
Moderate
F50C Architectural residue maintaining structure of
aminoacylation site
Reduced rate of aminoacylation due to
instability of alanine- and ATP-binding sites and
impaired alanyl-adenylate formation
L truncating mutation
R199C Catalytic residue involved in ATP binding Reduced rate of tRNA aminoacylation due to
affected ATP-binding and impaired
alanyl-adenylate formation
L A77V, F131del,
truncating mutations
E405K Structural residue within the tRNA recognition
subdomain of the aminoacylation domain
Partly reduced rate of tRNA aminoacylation
due to structural instability in the tRNA
recognition fold
L G965R
Almost all listed residues are invariant within AlaRSs, except R592. (C, cardiomyopathy; L, leukodystrophy).
protein stability, as they are all surface exposed (red color-coded
in Figure 7). However, each of these mutations is predicted
to result in dramatic reduction of aminoacylation rate due
to effects on substrate binding. In case of A77V (invariant
residue in all AlaRSs) the binding and activation of alanine
is likely to be affected. Y539C and R592W are predicted to
impair tRNA binding and stabilization within the aminoacy-
lation site by affecting interactions between the linker and
β-barrel that we propose to be important for binding and
securing acceptor stem of tRNAAla within the aminoacylation
domain.
Moderate
The F50C, R199C, and E405K (residues F73, E202, and K416 in
A. fulgidus, respectively) changes (orange color-coded in Figure 7)
affect structural residues and are predicted to cause local structural
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disturbances within the aminoacylation domain leading to partial
reduction of aminoacylation activity. The F50C mutant modeled
in yeast showed partial reduction of tRNAAla charging and protein
instability, which became noticeable only at a higher tempera-
ture (Dallabona et al., 2014). These results are in line with our
structural predictions.
In conclusion, our analysis of the homology model predicts
that the missense mutations in the first two categories, affect-
ing overall structure and substrate binding, severely compromise
the aminoacylation by the synthetase, which is also true for the
truncating mutations, whereas the missense mutations in the
third category result in reduced function but with some retained
aminoacylation activity. Combining the data of the compound
heterozygous mutations in each patient clearly shows that all
patients with leukodystrophy have combinations where one allele
is in one of the two severe categories or is a truncating muta-
tion and the other allele is in the third, moderate category,
whereas all mutations of the cardiomyopathy patients are severe
(Figure 8).
DISCUSSION
The tissue-specificity of mitochondrial diseases is puzzling. The
pathogenic mechanisms behind the tissue-specific manifestations
are likely to involve cell type-specific mitochondrial functions and
metabolite requirements, in addition to defects of ATP production
by oxidative phosphorylation (Nunnari and Suomalainen, 2012).
Differential basal mRNA expression levels of mtARSs have been
suggested to contribute to the tissue-specificity, as brain, mus-
cle, and heart were found to have low levels of mtARS mRNAs
compared to other tissues (Florentz et al., 2013). The example of
AARS2, however, shows that mutations in the same mtARS can
also give rise to highly different tissue-specific diseases.
Our previous hypothesis for the cardiomyopathy-related
R592W was that it affected tRNA binding in the editing domain
and thus interfered with the proofreading of mischarged tRNAs.
The homology modeling of human mtAlaRS, based on the new
resolved structure of AlaRS of A. fulgidus, suggested instead that
all domains of the synthetase, including the editing domain, have
an important role in tRNA binding for aminoacylation. We spec-
ulate whether this unique way of cooperative tRNA binding for
aminoacylation in AlaRSs might explain why the mtAlaRS has a
preserved editing domainwhereasmost othermitochondrialARSs
do not. For example, editing activity was lost during the evolution
of mtPheRS (Roy et al., 2005; Elo et al., 2012), and the editing
active site of mtLeuRS is not operational (Lue and Kelley, 2005).
Although the change at residue R592 does not appear to affect the
editing active site, we cannot rule out an effect on editing activity,
but we propose that the crucial consequence is on tRNA binding
for aminoacylation.
We suggest that the two distinct phenotypes caused by AARS2
mutations are simply caused by differential effects on aminoacyla-
tion, with cardiomyopathy resulting from highly severe reduction
in aminoacylation activity, and leukodystrophy resulting from
only partial reduction in activity. This conclusion could be reached
only by careful analysis of the combined mutations found in
the patients. The clinical feature of the cardiomyopathy patients
was the heart defect, although OXPHOS defects could be seen
also in muscle and brain. This suggests that the patients had a
combined tissue-involvement that can be expected when mito-
chondrial protein synthesis is significantly compromised, and that
other tissues would have also suffered, had the patients lived
longer.
We have previously proposed that severe defects of mitochon-
drial translation manifest in the heart immediately or soon after
FIGURE 8 | Classification of mutations based on structural
predictions. The lines between mutation categories connect the
compound heterozygous mutations identified in individual cardiomyopathy
patients (with red lines), and leukodystrophy patients (with blue lines).
The three categories at the top are predicted to have a severe effect
on the aminoacylation function of the synthetase, whereas the
mutations in the lower category are predicted to retain partial catalytic
activity.
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birth (Ahola et al., 2014), most often leading to early death. How-
ever, those few patients who survived the early severe cardiac
disease (Carroll et al., 2013; Haack et al., 2013; Ahola et al., 2014)
stabilized for their heart function after a few years of age, but later
tended to develop a brain disease. These findings suggest a special
requirement formitochondrial protein synthesis in the heart in the
early life, which can be partially compensated for after a critical
window of sensitivity, only to be followed by manifestations in the
sensitive organ of later childhood-adulthood years, the brain. This
hypothesis is also supported by our current findings: the severe
AARS2 mutations manifested in the heart soon after birth – or
even in late pregnancy – whereas the partial reduction of the syn-
thetase function manifested from 2 to 40 years of age in the brain
(Dallabona et al., 2014).
In the future, in vivo studies on the partial retained activity of
the leukodystrophy mutations – sufficient for heart function but
limiting for brain function during later years – are warranted, to
get further insight into the particular events taking place in the
heart and in the brain, constituting ‘the narrow permissive win-
dow for disease manifestation’ (Steenweg et al., 2012; Ahola et al.,
2014). The roles of amino acid availability and varying mtARS
expression levels in different developmental stages of tissues, as
well as the indispensable level of mitochondrial protein synthesis
in each stage and cell type, are of interest.
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